Bio Core
Exploring Scientific Community

International Journal of Case Studies in Clinical Research

Research Artical   **Open Access**

Multimodality DiagnosticApproach in Cardiac Sarcoidosis: from ECG to Magnetic Resonance Imaging

S.A.M. Said[1*], S. Post[1], R. de Nooijer[1], R. Nijhuis[1], H.H.D. Idzerda[1], J.W. op den Akker[2], O. Kessels[2], N.R.L. Wagenaar[3], A. Agool[3], C.D. Heymans[4]

[1]Salah AM Said, Department of Cardiology, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[1]Simone Post, Department of Cardiology, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[1]Ramon de Nooijer, Department of Cardiology, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[1]Rogier Nijhuis, Department of Cardiology, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[1]Herman Idzerda, Department of Cardiology, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[2]Oswald Kessels, Department of Radiodiagnostics, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[2]Jeroen op de Akker, Department of Radiodiagnostics, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[3]Nils Wagenaar, Department of Nuclear Medicine, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[3]Ali Agool, Department of Nuclear Medicine, Hospital Group Twente, Almelo-Hengelo, The Netherlands
[4]Carmencita Heymans, Pathologic Anatomy, Laboratory Pathology Oost Nederland, Hengelo, The Netherlands

*Corresponding Author: Salah A.M. Said, MD, PhD, FESC, Department of Cardiology, Hospital Group Twente, Geerdinksweg 141, 7555 DL Hengelo, the Netherlands. samsaid@home.nl **.** Telephone : + 31 88 708 5286 Fax : + 31 88 708 5289

Abstract

Aim: To describe the non-invasive multi-imaging options in patients who develop ventricular, supraventricular arrhythmias and conduction defects as a manifestation of cardiac sarcoidosis (CS) with biopsy documented systemic sarcoidosis.

Method: We report four cases of patients with extra-cardiac sarcoidosis presented with different manifestations of CS.

Results: CS was presented by ventricular tachycardia, total AV block, paroxysmal atrial fibrillation, persistent atrial flutter, complete right bundle branch block and multifocal PVC's. Moderate diastolic dysfunction (DD) was detected on echocardiography in one patient and mild DD in two patients. Systemic sarcoidosis was histologically and/or cytologically confirmed in all patients. No endomyocardial biopsy was performed. 18F-fluorodeoxyglucose positron emission tomography (FDG PET) was performed in three patients and cardiovascular magnetic resonance imaging (cMRI) was undertaken in 3. Merging of FDG PET with cMRI images revealed inflammatory activity at the sites of late gadolinium enhancement (LGE). All subjects were treated medically with a combination of prednisolone and methotrexate or azathioprine. A dual chamber implantable cardioverter-defibrillator (ICD) was implanted in three patients and the fourth received a dual chamber pacemaker. Transthoracic echocardiography findings of diastolic dysfunction were detected in one patient.

Conclusions: Non-invasive multi-imaging diagnostic approach is useful in patients with biopsy-proven extra-cardiac sarcoidosis who develop conduction disorder, supraventricular or ventricular tachyarrhythmias to confirm cardiac involvement and monitor treatment.

Introduction

Sarcoidosis is a systemic inflammatory disorder with unknown etiology which is characterized by the formation of non-caseating giant-cell epitheloid granulomas affecting many organ systems. Most commonly, it localizes in the lungs, hilar lymph nodes and skin.1,2 Cardiac sarcoidosis (CS) is a challenging diagnosis due to the often focal nature of cardiac involvement. CS may be manifested by ventricular tachycardia (VT), high grade heart block, heart failure or sudden death. 3,4 Cardiac manifestations are reported in 2.3% - 5% of the patients with systemic sarcoidosis, 5,6 but a higher percentage of 8% of cardiac involvement has been seen in the World Trade Center survivals. 7 The prevalence of CS in systemic sarcoidosis patients is estimated at 39% - 50%.4,8 In autopsy series of patients with systemic sarcoidosis, CS was found in 27% to 40% 9,10 of patients.

In this paper, we present 4 adult patients with non-invasively diagnosed cardiac sarcoidosis who presented with variable clinical manifestations. Diagnoses of CS was supported by extra-cardiac biopsy of lymph node and/or lung. The multimodality imaging techniques for diagnosis of cardiac sarcoidosis are briefly described.

Case presentations

Methods

We present 4 adult patients with non-invasively diagnosed cardiac sarcoidosis who presented with different clinical pictures. All clinical, diagnostic and therapeutic characteristics of the four patients (2 females; mean age 54.5, range 47-71 years) (Table 1) are described. The multimodality imaging techniques (Figures 1-4) for diagnosis of cardiac sarcoidosis are highlighted.

Results

The clinical presentations were dizziness (n =3), palpitation (n =2), dyspnea (n =2) and fatigue (n =2). Profuse sweating was present in 2 patients. Monomorphic ventricular tachycardia was found in one patient (patient 1), successfully terminated by electrical cardioversion; two patients (patients 1 and 3) (CHA2DS2-VASc score = 0) developed supraventricular arrhythmias (atrial fibrillation (AF), atrial flutter and atrial tachycardia). AF was treated with chemical conversion. Electrocardiographic (ECG) abnormalities were present in all. Twelve-lead ECG demonstrated sinus rhythm with first degree atrioventricular block (AV) in one patient (patient 1) and total AV block (TAVB) in another (patient 2). Prolonged QTc interval was present in one patient (patient 1) and complete right bundle branch block in another (patient 3). Two patients (patients 3 and 4) complained of unifocal and multifocal premature ventricular beats, respectively. A previous history of treated arterial hypertension and known systemic sarcoidosis (since 2008) was present in one patient (patient 2) and erythema nodosum was diagnosed in 2006 in another (patient 4). After discontinuation of beta blocker and on monitoring of patient 2, no signs of conduction recovery was observed, she remained in TAVB. Chest X-ray was abnormal in all four patients. Troponin T (normal range < 14 ng/l) was mildly elevated in three patients (patients 1, 2 and 3). Left ventricle systolic function and dimensions were normal in all patients. Mild diastolic dysfunction was detected in two patients (patient 1 and 4) and moderate in one (patient 2). Coronary angiography revealed normal coronary arteries in three and was not performed in one of the patients (patient 2). Myocardial


Figure 1A: Admission electrocardiogram showing broad-complex monomorphic ventricular tachycardia of 228 beats/min.
Figure 1B: ECG: depicting persistent atrial flutter with 4:1 AV block and sporadic premature ventricular contraction.
Figure 1C: Paratracheal (station 2R) lymph node biopsy, Hematoxylin & Eosin (H+E) staining demonstrating noncaseating, multinucleated giant cell granulomas without necrosis (double-headed arrow), magnification 200x.
Figure 1D: Whole body FDG-PET scan demonstrates showing the sarcoidosis activity, increased FDG uptake in the right ventricle and atrium with multiple mediastinal and abdominal lymphadenopathy (arrows).
 Figure 1E: increased FDG uptake in the right ventricle and atrium.
Figure 1F: FDG PET and MRI LGE fusion image localizes the cardiac FDG uptake in the right ventricular and atrial walls. Left panel: MRI LGE, right panel: fusion images of MRI LGE and FDG PET, demonstrating LGE producing the same zones of segmental wall thinning (arrows) with a mid-wall pattern in the right ventricle and right atrial wall.

Fig.2A Fig.2B Fig.2C Fig.2D Fig.2E

Fig.3A Fig.3B Fig.3C Fig.3D

Fig.4A Fig.4B Fig.4C Fig.4E Fig.4F Fig.4G

Table 1: Data of four patients with histologically/cytologicalley proven cardiac sarcoidosis.

Case/age/ sex (years)	Clin. present	Blood pressure (mmHg) on admission	ECG	Troponine T (N < 14 ng/l)	Chest X-ray	TTE	CAG	Positive biopsy	^{18}F-FDG-PET-CT uptake	Cardiac MRI (LGE)	Management
1- 52M	Dizziness Tachycardia	82/60	VT, AFl, transient 1e degree AV block and prolonged QTc	27	bilateral pleural effusion without signs of pulmonary venous congestion or hilar lymphadenopathy	DD-I, LVEF: 52.3% . D-sign	N	Para-tracheal lymph node (station 2R)	Increased activity RV and RA. Mediastinal and abdominal para-aortic lymphadenopathy	LGE in RV, RVOT, RA and IAS. Meditational, paratracheal and paraaortic lymphadenopathy. LVEF: 64%	prednisolone+ azathioprine and DDD ICD
2- 71F	Dizziness Dyspnea	134/41	TAVB	17	Mediastinal and hilar lymphadenopathy	DD-II, Mild AR, MR and TR. LVEF: 62.6%	not performed	Lymph node EUS (station 7)	Extensive uptake in both lungs, mediastinal, supraclavicular and inguinal. Uptake in LV myocardium	not performed	prednisolone + methotrexate, DDDR pacemaker
3- 48M	Palpitation Dyspnea	120/68	SR, PVC's, PAC's, AT, PAF, RBBB	19	Mediastinal lymphadenopathy. Parenchymal nodular pattern of perilymphatic distribution in RUL	N . LVEF: 60.3%	N	Right upper lung lobe (RUL)	Not performed	TRIM sequence: Edema Anterospetal and inferoseptal. LGE with fibrosis mid-wall anteroseptal and inferoseptal of RV wall, moderator band and both papillary muscles. Interstitial lesions RUL and mediastinal lymphadenopathy. LVEF: 57%	Prednisolone + methotrexate and DDD ICD
4- 47F	Dizziness Palpitation Fatigue	140/80	SR, multifocal PVC's	14	Hilar lymphadenopathy	DD-I . LVEF: 58.4%	N	Inguinal lymph node	Excessive FDG uptake infraclavicular, mediasinal, abdominal and inguinal lymphadenopathy and myocardial uptake (septum and apex)	Edema and delayed enhancement in the basal anteroseptal area LV, moderator band and apical inferoseptal region of both ventricles. Mediastinal lymphadenopathy. LVEF: 67%	Prednisolone + methotrexate and DDD ICD

Abbreviations: AF= atrial fibrillation, AFl= atrial flutter, AR= aortic regurgitation, AT= atrial tachycardia, AV= atrioventricular, CAG= coronary angiography, DDD= dual chamber, DDDR= dual chamber rate responsive pacemaker, DD= diastolic dysfunction, ECG= electrocardiogram, EUS= endoscopic ultrasound, F= female, 18FDG-PET-CT= 18F-fluorodeoxyglucose positron emission tomography-computed tomography, ICD= implantable cardioverter-defibrillator, LGE= late gadolinium enhancement, LV= left ventricle, LVEF= left ventricle ejection fraction, M= male, MR= mitral regurgitation, MRI= magnetic resonance imaging, N= normal, PAC's= premature atrial contractions, PVC's= premature ventricular contractions, RBBB= right bundle branch block, RA= right atrium, RV= right ventricle, RVOT= right ventricle outflow tract, RUL= right upper lobe, SR= sinus rhythm, TAVB= total atrioventricular block, TIRM= Turbo inversion recovery magnitude sequence, TR= tricuspid regurgitation, TTE= transthoracic echocardiography, VT= ventricular tachycardia.

perfusion imaging demonstrated normal perfusion without defects and no signs of ischemia (patient 2). 18F-fluorodeoxyglucose positron emission tomography (FDG PET) was performed in three patients (patients 1, 2 and 4) demonstrating increased activity in all and cardiovascular magnetic resonance imaging (cMRI) was undertaken in 3 revealing late gadolinium enhancement in all. Merging of FDG PET with cMRI images revealed inflammatory activity at the sites of late gadolinium enhancement (LGE). FDG PET showed increased activity in the right ventricle and right atrium as well as mediastinal and abdominal para-aortic lymphadenopathy (patient 1), augmented FDG uptake in the left ventricle (patient 2) and visible activity in cervical, mediastinal, hilar, para-aortic abdominal and inguinal lymph nodes with also myocardial septal and apical localization in the left ventricle (patient 4) (Figure 1-4). Systemic sarcoidosis was histologically and/or cytologically (paratracheal lymph node (patient 1), lymph node station 7 (patient 2), right upper lung lobe (patient 3) and inguinal lymph node (patient 4)) confirmed in all patients. No endomyocardial biopsy was performed.

Three patients (patients 1, 3 and 4) underwent dual chamber implantable cardioverter-defibrillator (ICD) placement and permanent dual chamber pacemaker was implanted in one patient (patient 2). Treatment with a combination of prednisolone and methotrexate was initiated in three patients and a combination of prednisolone and azathioprine in one (patient 1).

Discussion

History and incidence

Cardiac sarcoidosis (CS), is a highly lethal disorder due to heart failure, complex ventricular arrhythmias,3 or even sudden cardiac death.9 In 1929, cardiac involvement was first recognized in an autopsy case11 and in 1952, Longcope et al, described myocardial involvement in 20% of a large series of autopsied cases of sarcoidosis.12 Later autopsy studies have revealed that between 27% and 40% of patients with systemic sarcoidosis have myocardial involvement.9 10,13

Clinical presentations

CS may be asymptomatic in 3.7-54.9% of patients undergoing different imaging studies.14 15 Clinical presentations of CS, reported in decreasing order of frequency, are ventricular tachycardia (VT) 21%, syncope 17%, congestive heart failure 14% and palpitation in 6% of subjects. 16 Furthermore, in CS, sudden death due to ventricular arrhythmia accounts for 30-65% in this population. 17,18 It has been observed that the degree and severity of pulmonary involvement did not predict and is not correlated with cardiac sarcoidosis. 4,19 CS can be found prior, after or concurrently with involvement of the lungs or other systems and organs. In our female patients, CS took 5 to 7 years before it became manifest; one in association with pulmonary sarcoidosis and in the other following cutaneous sarcoidosis, respectively.

Diagnosis

Revised Japanese Ministry of Health Welfare (JMHW) criteria and biopsy results were used to confirm the diagnosis of CS. Systemic sarcoidosis is a clinical diagnosis supported by laboratory, radiologic and nuclear imaging studies and histopathologic or cytologic examinations. Furthermore, Heart Rhythm Society expert consensus recommendations on criteria for the diagnosis of CS provides 2 pathways to a diagnosis of CS: First, histological diagnosis from myocardial tissue and second, clinical non-invasive and invasive imaging studies for establishing the diagnosis of CS.19

When CS is suspected, several diagnostic modalities have been recommended. Assessment by TTE, ambulatory ECG monitoring, myocardial perfusion imaging, cardiac MRI or 18F-FDG PET-CT are recommended.

Electrocardiography: ECG findings of CS are fractionation of QRS complex (75%), RBBB (19-23.1%) and LBBB (3.8%-6%). 16,20 The ECG of the first patient showed an episode of sustained monomorphic VT. Recently, it has been reported that isolated cardiac sarcoidosis may be highly suspected in subjects with sustained ventricular tachycardia. 21 In a prospective study, four of 14 (28%) patients presenting with monomorphic VT had CS as the causing etiology. 22 Persistent atrial flutter occurred also in the first patient and paroxysmal atrial fibrillation was documented in the third patient. Multifocal ventricular premature contractions were found on the ECG of the fourth patient. Commonly, atrial arrhythmias occur less frequently in CS. 23 Various degrees of AV block occurs in 26-67% and complete heart block in 23-30% of CS cases. 16,17,18 Recently, in a prospective study of patients with unexplained total AV block, previously undiagnosed CS was found in 34% of the patients. 24 Resting ECG has low sensitivity (8%) for detecting CS. 4

In patients with proven systemic sarcoidosis ECG alterations

can be used as a marker of cardiac involvement. Presence of fragmented QRS or a bundle branch block or a Q wave increase the likelihood of cardiac sarcoidosis. Right bundle branch block was found in one or our patients. Corrected QT interval was within the normal limits in three subjects ranging from 405 to 426 and in one male patient it was slightly increased to 468 msec.

Echocardiography is readily available and provides valuable information of myocardial, valvular, pericardial, and congenital heart defects associated with ventricular arrhythmias. It is recommended in subjects with ventricular arrhythmias who are suspected of having structural heart disease. 3 In our series, the echocardiography images were optimal for judgment which excluded cardiomyopathy and pericardial effusion with slightly abnormal dilatation of the RV with septal D-sign in one patient (patient 1) suggesting echoardiographic pulmonary hypertension (PHT). In three patients, various degrees (grade I and II) of diastolic dysfunction were detected. Recently, Joyce et al, have shown that RV dysfunction detected using right ventricular global longitudinal peak systolic strain (RVGLS) is commonly found in sarcoidosis in the absence of manifest cardiac involvement or pulmonary hypertension. 25

LV dysfunction, WMAs and abnormal septal thickness are most frequently reported. 26 27 As early as 1996, Fahy et al., reported LV diastolic dysfunction in 14% (7/50) of patients (6/7= 86% had normal systolic function) with biopsy-proved pulmonary sarcoidosis.26 Chiu et al., reported echocardiographic manifestations in 52 patients with CS, they found WMAs in 77% (40/52), impaired LV function in 54% (28/52), thinning of basal IVS in 52% (27/52), thinning of LV free wall in 35% (18/52) and apical aneurysm in 23% (12/52).27 Smedema et al., found that WMAs, MR, LV dimensions and diastolic and systolic function correlated with the degree of myocardial involvement detected by cardiac MRI.14

Coronary angiography (CAG) is pivotal in patients with life threatening ventricular tachyarrhythmias in establishing the presence of significant atherothrombotic coronary heart disease (CHD). CAG is commonly performed as part of the diagnostic evaluation, to rule out coronary vessel anomalies or malformations. CHD was ruled out in our presented patients by absence of anginal complaints and normal findings on CAG and normal myocardial perfusion imaging.

Cardiac MRI is a useful diagnostic utility when echocardiography is unable to provide accurate assessment of LV or RV function. In addition to echocardiography, CMRI can characterize tissue revealing inflammation and fibrosis. Diagnostic MRI findings in cardiac sarcoidosis are midwall rather than subendocardial or transmural LGE not corresponding to any particular coronary artery distribution. 13 LGE has a high sensitivity (100%) and moderate specificity (78%) for diagnosing cardiac sarcoidosis suggesting that myocardial scars indicated by LGE were an independent predictor of sudden cardiac death in patients with suspected CS. 28 The new Japanese guidelines consider LGE as a major criterion of CS. In our current case series, MRI revealed several features of cardiac involvement such as delayed enhancement in RV and RA (patient 1), RV midmyocardial late enhancement, edema and fibrosis of RV (patient 3) and edema of basal anteroseptal region of LV, apical inferoseptal area of both ventricles and moderator band (patient 4). With cardiac MRI both scar and myocardial edema can be demonstrated. It has been reported that LGE may be localized in the basal portion of the septal wall with nodular involvement which are suggestive of cardiac sarcoidosis. 29

18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET). Cardiac PET may play a pivotal role in the diagnosis and treatment monitoring of patients with CS. 30 Blankstein et al., identified adverse cardiac events in subjects with known or suspected CS using cardiac PET imaging. Patients with either abnormality in both myocardial perfusion and metabolism (active inflammation) or RV involvement had a three-fold increase in the rate of adverse events. 16 In the current case series, RV involvement was seen in three subjects.

FDG PET can detect sarcoid lesions of the whole body and might be more sensitive as a diagnostic tool in detecting CS (Fig. 1E, Fig. 2B and Fig. 4B). PET-CT has been recommended for patients with cutaneous lesions, as was the case in (patient 4) who had a past history of erythema nodosum. 31

In 2013, abnormal 18F-FDG-PET/82Rubidium scans were found in 60% of patients following a high fat/low carbohydrate diet. 16 In 29% of patients, cardiac PET findings were predictors of adverse events with the presence of both a perfusion defect (82Rubidium/perfusion) and abnormal 18F-FDG uptake (metabolism/inflammation activity).

In patients with cutaneous sarcoidosis, 18F-FDG-PET or gallium scintigraphy detected cardiac involvement in 4 out of 12 patients (33%). 31 In another study by Youssef et al., found that pooled estimates for 18F-FDG PET yielded higher sensitivity (89%) and specificity (78%) for establishing CS in comparison with the Ontario registry which yielded sensitivity of 79% and specificity of 70%. 8

Biopsy

The most common histological features of sarcoidosis are non-caseating sarcoid granulomas with limited lymphocyte infiltration and patchy fibrosis 32 (Fig. 1D, Fig. 3C and Fig. 4D). Endomyocardial biopsy (EMB) is not indicated as long as systemic sarcoidosis has been confirmed by lymph node biopsy or extracardiac biopsy. 33 EMB has a low sensitivity of 30% with a poor yield due to the focal nature of CS. 34 Systemic sarcoidosis was confirmed by biopsy of the paratracheal (station 2R) lymph node (patient 1), lymph node endoscopic ultrasound fine-needle biopsy (EUS) of station 7 (patient 2) and right upper lung lobe (patient 3) and inguinal lymph node (patient 4) revealing granulomatous inflammation without specific features or signs of Mycobacterium tuberculosis infection. In none of our current patients EMB was performed. EMB has proven useful for histologic diagnosis of CS. EMB has several limitations (invasive procedure and insensitivity due to focal involvement of the myocardium).

Differential diagnosis

CS should be differentiated from arrhythmogenic right ventricular dysplasia/ cardiomyopathy (ARVD/C), ischemic heart disease, Lyme disease, giant cell myocarditis and dilated cardiomyopathy. Patients with CS have lower left ventricular ejection fraction

(LVEF) than ARVD/C, and LV septal involvement is seen exclusively in CS patients. In MRI comparison study, Steckman et al., found greater late gadolinium enhancement in CS patients compared with ARVD/C patients. 35 In CS, the LV involvement is more common 36, CS should also be differentiated from conditions associated with the development of inverted precordial T-waves. 37

Lyme carditis may be excluded by negative serology. Lyme carditis occurs in 0.3-8% of Borrelia Burgdorferi infection and it is usually self-limiting when appropriately treated with antibiotics. 3 With regard to ischemic heart disease, the first patient had a normal coronary arterial tree on his CAG. The slight troponin elevation and inverted T-wave in the precordial leads may be attributed to the tachyarrhythmia and considered as "cardiac memory" subsequent to the tachyarrhythmias. Furthermore, in our series, ischemic heart disease was excluded because of absence of anginal complaints associated with normal myocardial perfusion imaging in the other patients. In the current series, myocarditis was less likely because cardiac MRI findings were specific for sarcoidosis. Cardiac MRI findings that show patchy focal edema in the subepicardium and/or subepicardially distributed late gadolinium enhancement are indicative of myocarditis. Furthermore, in the current series, combining the images of cardiac MRI with FDG PET-CT demonstrated that the late gadolinium enhancement corresponded well to the increased FDG uptake. In our patients, the diagnosis of cardiac sarcoidosis was established based on the combination of clinical presentation, findings on ECG (sustained monomorphic ventricular tachycardia, persistent atrial flutter, paroxysmal atrial fibrillation and AV conduction abnormalities), 18F-FDG-PET-CT and cardiac MRI images.

Pharmacologic (corticosteroids and immune-suppression) and non-pharmacologic (device therapy of implantable cardioverter-defibrillator (ICD) and pacemaker) treatment was initiated.

Management

CS is associated with high rate of mortality due to heart failure, complex ventricular arrhythmias, or even sudden cardiac death. 3,4 ICD implantation is a class IIA indication in patients with cardiac sarcoidosis for primary prevention and class I for secondary prevention. 19 Studies describing randomized controlled trials of therapy are lacking in cardiac sarcoidosis. The cornerstone of therapy for sarcoidosis is immune-suppression (corticosteroids) either alone or combined with other immune modulators (methotrexate, azathioprine). It has been postulated that pharmacologic treatment can promote fibrosis which in turn can facilitate more VT substrate. Corticosteroids improve survival, and pacemaker implantation for advanced heart block and ICD treatment should be considered to decrease the incidence of sudden cardiac death. In an electrophysiology study by Kumar et al, catheter ablation was found to be able to terminate VT storm resulting in reduction in the burden of defibrillator shocks in the majority of patients with CS. 38 Our first patient had initially an episode of sustained VT necessitating electrical cardioversion in the acute phase and the placement of an implantable cardioverter-defibrillator for secondary prevention. The second patient suffered an attack of a total heart block requiring dual chamber pacemaker implantation. The other two patients were managed with medical treatment including prednisone and methotrexate accompanied with prophylactic ICD implantation.

Patients at higher risk of ventricular arrhythmias, conduction abnormalities should be considered for early corticosteroid/immunosuppressive treatment, ICD therapy or permanent pacemaker implantation. Normal LV function is the most significant predictor of high survival 5-year rate (89% vs 27%). 18

Patients are considered at higher risk when there is a poor New York Heart Association functional class, increased left ventricular end diastolic diameter, reduced ejection fraction and sustained VT. 39 Furthermore, LGE positive patients had higher rate of adverse events and sudden cardiac death. 28,40

Conclusion

In conclusion, cardiac involvement of systemic sarcoidosis is increasingly detected. The spectrum of ventricular, supraventricular arrhythmias and AV block may serve as the initial sign of presence of CS. Besides MRI, FDG PET is pivotal, not only for diagnosis, but also, as noted in this study, for monitoring of therapeutic response. Diagnosis requires high index of suspicion and multidisciplinary teamwork. The diagnosis of CS can often be established with non-invasive modalities when consistent clinical and/or histological/cytological findings are consequent with systemic sarcoidosis. Identifying early cardiac dysfunction with non-invasive modalities among subjects with systemic sarcoidosis is a critical step in providing opportunities for risk stratification and early intervention to decrease the associated risk of long term cardiovascular disease in this high-risk group of patients.

Reference

1. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet. 2014;383:1155-67.

2. Crystal RG, Gadek JE, Ferrans VJ, et al. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med. 1981;70:542-68.

3. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:746-837.

4. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426-35.

5. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-9.

6. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253-8.

7. Crowley LE, Herbert R, Moline JM, et al. "Sarcoid like" granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med. 2011;54:175-84.

8. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-8.

9. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-11.

10. Sekhri V, Sanal S, Delorenzo LJ, et al. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7:546-54.

11. Bernstein M, Konzelman FW, Sidlick DM. Boeck's sarcoid: report of a case with visceral involvement. Arch Intern Med. 1929;4:721-34.

12. Longcope WT, Freiman DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine (Baltimore). 1952;31:1-132.

13. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-90.

14. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest. 2005;128:30-5.

15. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26:762-7.

16. Blankstein R, Osborne M, Naya M, et al. Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients with Suspected Cardiac Sarcoidosis. J Am Coll Cardiol. 2013.

17. Roberts WC, McAllister HA, Jr., Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86-108.

18. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-10.

19. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-23.

20. Schuller JL, Olson MD, Zipse MM, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011;22:1243-8.

21. Huitema MP, Swaans MJ, Grutters JC, et al. A case highly suspicious of isolated cardiac sarcoidosis. Neth Heart J. 2016;24:433-4.

22. Nery PB, Mc Ardle BA, Redpath CJ, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2014;37:364-74.

23. Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med. 2009;15:507-12.

24. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25:875-81.

25. Joyce E, Kamperidis V, Ninaber MK, et al. Prevalence and Correlates of Early Right Ventricular Dysfunction in Sarcoidosis and Its Association with Outcome. J Am Soc Echocardiogr. 2016;29:871-8.

26. Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest. 1996;109:62-6.

27. Chiu CZ, Nakatani S, Yamagishi M, et al. Echocardiographic manifestations in patients with cardiac sarcoidosis. J Med Ultrasound. 2002;10:135-40.

28. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501-11.

29. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. Am J Roentgenol. 2005;184:249-54.

30. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030-6.

31. Nakamura S, Hashimoto Y, Nishi K, et al. High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series. J Med Case Rep. 2014;8:17.

32. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18:733-46.

33. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336-46.

34. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914-31.

35. Steckman DA, Schneider PM, Schuller JL, et al. Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2012;110:575-9.

36. Sharma PS, Lubahn JG, Donsky AS, et al. Diagnosing cardiac sarcoidosis clinically without tissue confirmation. Proc (Bayl Univ Med Cent). 2009;22:236-8.

37. Said SA, Bloo R, de Nooijer R, et al. Cardiac and non-cardiac causes of T-wave inversion in the precordial leads in adult subjects: A Dutch case series and review of the literature. World J Cardiol. 2015;7:86-100.

38. Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:87-93.

39. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282-8.

40. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-77.